Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 90

Sort by

Sort Order Select

Journal Articles

LONG-TERM Results of the Frontline Dasatinib/Blinatumomabprotocol (D-ALBA, GIMEMA LAL2116) for Adult Ph+ Acutelymphoblastic Leukemia

Robin Foà, Renato Bassan, Loredana Elia, Alfonso Piciocchi, Stefano Soddu, Monica Messina, Felicetto Ferrara, Monia Lunghi, Antonino Mulè, Massimiliano Bonifacio, Nicola Fracchiolla, Prassede Salutari, Paola Fazi, Anna Guarini, Alessandro Rambaldi, Sabina Chiaretti

Blood (2023) 142 (Supplement 1): 4250.

https://doi.org/10.1182/blood-2023-187773

Published: 2023

Journal Articles

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Blood (2023) 142 (Supplement 1): 1905.

https://doi.org/10.1182/blood-2023-181597

Published: 2023

Journal Articles

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Blood (2023) 142 (Supplement 1): 4399.

https://doi.org/10.1182/blood-2023-182946

Published: 2023

Journal Articles

Endothelial cell–leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities

Blood (2023) 141 (5): 503–518.

https://doi.org/10.1182/blood.2022015414

Published: 2023

Includes: Supplemental data

Journal Articles

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study

Blood (2021) 138 (25): 2727–2730.

https://doi.org/10.1182/blood.2021011883

Published: 2021

Includes: Supplemental data

Journal Articles

Host immune system modulation in Ph + acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab

Maria Cristina Puzzolo, Giulia Radice, Nadia Peragine, Maria Stefania de Propris, Paola Mariglia, Marco Vignetti, Antonella Vitale, Renato Bassan, Mario Annunziata, Gianluca Gaidano, Alessandro Rambaldi, Sabina Chiaretti, Anna Guarini, Robin Foà

Blood (2021) 138 (22): 2290–2293.

https://doi.org/10.1182/blood.2021011822

Published: 2021

Includes: Supplemental data

Journal Articles

A Predictive Endothelial-Leukemia Pre-Clinical Platform to Uncover Drug Vulnerabilities for Personalized Treatments

Blood (2021) 138 (Supplement 1): 704.

https://doi.org/10.1182/blood-2021-153300

Published: 2021

Journal Articles

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

Francesca Romana Mauro, MD PhD, Gianluigi Reda, MD, Valentina Arena, MS, Livio Trentin, MD, Marta Coscia, MD PhD, Paolo Sportoletti, MD, Luca Laurenti, MD, Gianluca Gaidano, Roberto Marasca, MD, Lorella Orsucci, MD, Roberta Murru, MD, Caterina Stelitano, Fiorella Ilariucci, MD, Donato Mannina, MD, Massimo Massaia, MD, Gian Matteo Rigolin, Lydia Scarfo, Monia Marchetti, MD, Luciano Levato, MD, Monica Tani, MD, Annalisa Arcari, MD, Gerardo Musuraca, MD, Marina Deodato, Piero Galieni, Catello Califano, MD, Daniela Gottardi, MD, Anna Marina Liberati, MD, Daniela Pietrasanta, MD, Stefano Molica, MD, Ramona Cassin, MD, Andrea Visentin, MDPhD, Candida Vitale, MDPhD, Gianfranco Lapietra, MD, Irene Della Starza, PhD, Maria Stefania De Propris, PhD, Sara Raponi, PhD, Mauro Nanni, PhD, Ilaria Del Giudice, MD PhD, Giorgia Giuliani, PhD, Marco Vignetti, MD, Anna Guarini, PhD, Francesco Albano, Antonino Neri, MD, Antonio Cuneo, MD, Robin Foà, MD

Blood (2020) 136 (Supplement 1): 47–49.

https://doi.org/10.1182/blood-2020-135922

Published: 2020

Journal Articles

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Alessandro Pulsoni, MD, Maria Elena Tosti, Statistician, Simone Ferrero, MD, Stefano Luminari, MD, Anna Marina Liberati, Natalia Cenfra, MD, Daniela Renzi, MD, Emanuela Zanni, MD, Carola Boccomini, MD, Andres JM Ferreri, MD, Sara Rattotti, Vittorio Ruggero Zilioli, MD, Patrizia Bernuzzi, MD, Silvia Bolis, MD, Gerardo Musuraca, MD, Luca Nassi, Tommasina Perrone, MD, Caterina Stelitano, MD, Antonella Anastasia, MD, Paolo Corradini, MD, Giovanni Partesotti, MD, Francesca Re, Emanuele Cencini, MD, Clara Mannarella, MD, Donato Mannina, MD, Anna Lia Molinari, MD, Monica Tani, MD, Giorgia Annechini, MD, Giovanni Manfredi Assanto, MD, Lavinia Grapulin, MD, Irene Della Starza, PhD, Marzia Cavalli, PhD, Lucia Anna De Novi, PhD, Elena Ciabatti, Barbara Mantoan, PhD, Anna Guarini, PhD, Luca Arcaini, Umberto Ricardi, MD, Valter Gattei, MD, Sara Galimberti, MD PhD, Marco Ladetto, MD, Ilaria Del Giudice, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 124.

https://doi.org/10.1182/blood-2019-123106

Published: 2019

Journal Articles

The Validation of the BCR/ABL1 -like Predictor across Laboratories Shows Reproducibility of Results

Sabina Chiaretti, MD PhD, Taherinasab Akram, Canichella Martina, Monica Messina, Alfonso Piciocchi, Cyril Šálek, MD PhD, Katerina Machova, Katerina Blagoevova, Jordi Ribera, PhD, Josep-Maria Ribera, MD PhD, Manja Meggendorfer, PhD, Claudia Haferlach, MD, Anna Guarini, PhD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 5211.

https://doi.org/10.1182/blood-2019-122116

Published: 2019

Journal Articles

Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience

Michela Ansuinelli, MD, Antonella Vitale, MD, Giovanna Pecoraro, MD, Saveria Capria, MD, Silvia Maria Trisolini, MD, Clara Minotti, MD, Claudio Cartoni, MD, Anna Maria Testi, MD, Maria Luisa Moleti, MD, Anna Paola Iori, MD, Walter Barberi, MD PhD, Irene Della Starza, PhD, Loredana Elia, Bs, Francesca Mancini, Maria Stefania De Propris, Anna Guarini, PhD, Sabina Chiaretti, MD PhD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 5121.

https://doi.org/10.1182/blood-2019-128156

Published: 2019

Journal Articles

Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial

Sabina Chiaretti, MD PhD, Renato Bassan, MD, Antonella Vitale, MD, Loredana Elia, Bs, Alfonso Piciocchi, Cristina Puzzolo, PhD, Martina Canichella, MD, Felicetto Ferrara, MD, Monia Lunghi, MD PhD, Francesco Fabbiano, MD, Massimiliano Bonifacio, MD, Nicola Fracchiolla, Prassede Salutari, MD, Alessandra Mancino, Bs, Marco Vignetti, MD, Anna Guarini, PhD, Alessandro Rambaldi, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 740.

https://doi.org/10.1182/blood-2019-128759

Published: 2019

Journal Articles

The Combination of Complex Karyotypes' Subtypes and IGHV Mutational Status Provides Prognostic and Predictive Information in Chronic Lymphocytic Leukemia

Blood (2018) 132 (Supplement 1): 1844.

https://doi.org/10.1182/blood-2018-99-114721

Published: 2018

Journal Articles

Digital-Droplet PCR, an Accurate Method for IG/TR PCR-MRD Stratification in Childhood Acute Lymphoblastic Leukemia

Irene Della Starza, PhD, Vittorio Nunes, Federica Lovisa, Daniela Silvestri, Marzia Cavalli, PhD, Andrea Garofalo, Mimma Campeggio, Lucia Anna De Novi, PhD, Carlotta Oggioni, Andrea Biondi, MD, Anna Guarini, PhD, Maria Grazia Valsecchi, PhD, Valentino Conter, MD, Giuseppe Basso, MD, Robin Foà, MD, Giovanni Cazzaniga, PhD

Blood (2018) 132 (Supplement 1): 1544.

https://doi.org/10.1182/blood-2018-99-117954

Published: 2018

Journal Articles

Clinical Significance of Occult Central Nervous System Disease in Adult ACUTE Lymphoblastic Leukemia. a Multicenter,Report from the Campus ALL/Gimema Network

Blood (2018) 132 (Supplement 1): 658.

https://doi.org/10.1182/blood-2018-99-114177

Published: 2018

Journal Articles

TP53 Clonal and Subclonal Architecture in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment

Ilaria Del Giudice, Luciana Cafforio, Luca Vincenzo Cappelli, MD, Caterina Ilari, PhD, Sara Raponi, Maria Stefania De Propris, Paola Mariglia, Francesca Romana Mauro, Marco Vignetti, Anna Guarini, PhD, Robin Foà, MD

Blood (2018) 132 (Supplement 1): 3119.

https://doi.org/10.1182/blood-2018-99-114232

Published: 2018

Journal Articles

Comparative Analysis between RQ-PCR, Digital-Droplet-PCR and Next-Generation-Sequencing (NGS) of Immunoglobulin/T-Cell Receptor Gene Rearrangements to Monitor Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia Patients

Irene Della Starza, PhD, Lucia Anna De Novi, PhD, Alessandra Santoro, PhD, Salemi Domenico, PhD, Marzia Cavalli, PhD, Roberta Soscia, Francesca Paoloni, Lucia Menale, Valerio Apicella, Caterina Ilari, PhD, Antonella Vitale, Marco Vignetti, MD, Renato Bassan, MD, Sabina Chiaretti, MD PhD, Anna Guarini, PhD, Robin Foà, MD

Blood (2018) 132 (Supplement 1): 2828.

https://doi.org/10.1182/blood-2018-99-118219

Published: 2018

Journal Articles

The Pro-Tumorigenic Vascular Niche Sustains the T-Cell Acute Lymphoblastic Leukemia Phenotype and Fosters Resistance to Therapy

Blood (2016) 128 (22): 279.

https://doi.org/10.1182/blood.V128.22.279.279

Published: 2016

Journal Articles

Early Stage Follicular Lymphoma. Predictive Role of Minimal Residual Disease (MRD) and Impact of MRD-Driven Treatment with Radiotherapy and Rituximab on Clinical Outcome

Alessandro Pulsoni, MD, Irene Della Starza, PhD, Maria Elena Tosti, statistician, Luca Vincenzo Cappelli, Giorgia Annechini, Marzia Cavalli, PhD, Lucia Anna De Novi, PhD, Gianna Maria D'Elia, Lavinia Grapulin, MD, Anna Guarini, Ilaria Del Giudice, MD PhD, Robin Foa

Blood (2016) 128 (22): 2959.

https://doi.org/10.1182/blood.V128.22.2959.2959

Published: 2016

Journal Articles

Comparative Analysis Between RQ-PCR and Digital Droplet PCR of BCL2/IGH Rearrangement in the Peripheral Blood and Bone Marrow of Early Stage Follicular Lymphoma

Marzia Cavalli, PhD, Lucia Anna De Novi, PhD, Irene Della Starza, PhD, Luca Cappelli, Vittorio Nunes, Alessandro Pulsoni, MD, Ilaria Del Giudice, MD PhD, Anna Guarini, Robin Foa

Blood (2016) 128 (22): 5308.

https://doi.org/10.1182/blood.V128.22.5308.5308

Published: 2016

NARROW

LONG-TERM Results of the Frontline Dasatinib/Blinatumomabprotocol (D-ALBA, GIMEMA LAL2116) for Adult Ph+ Acutelymphoblastic Leukemia

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Endothelial cell–leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study

Host immune system modulation in Ph + acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab

A Predictive Endothelial-Leukemia Pre-Clinical Platform to Uncover Drug Vulnerabilities for Personalized Treatments

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

The Validation of the BCR/ABL1 -like Predictor across Laboratories Shows Reproducibility of Results

Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience

Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial

The Combination of Complex Karyotypes' Subtypes and IGHV Mutational Status Provides Prognostic and Predictive Information in Chronic Lymphocytic Leukemia

Digital-Droplet PCR, an Accurate Method for IG/TR PCR-MRD Stratification in Childhood Acute Lymphoblastic Leukemia

Clinical Significance of Occult Central Nervous System Disease in Adult ACUTE Lymphoblastic Leukemia. a Multicenter,Report from the Campus ALL/Gimema Network

TP53 Clonal and Subclonal Architecture in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment

Comparative Analysis between RQ-PCR, Digital-Droplet-PCR and Next-Generation-Sequencing (NGS) of Immunoglobulin/T-Cell Receptor Gene Rearrangements to Monitor Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia Patients

The Pro-Tumorigenic Vascular Niche Sustains the T-Cell Acute Lymphoblastic Leukemia Phenotype and Fosters Resistance to Therapy

Early Stage Follicular Lymphoma. Predictive Role of Minimal Residual Disease (MRD) and Impact of MRD-Driven Treatment with Radiotherapy and Rituximab on Clinical Outcome

Comparative Analysis Between RQ-PCR and Digital Droplet PCR of BCL2/IGH Rearrangement in the Peripheral Blood and Bone Marrow of Early Stage Follicular Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only